GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Jenburkt Pharmaceuticals Ltd

Jenburkt Pharma Q2 FY27 Net Profit Rs. 1020.94 Lacs, Revenue Rs. 4831.82 Lacs

RESULTS ◆ Monitor Closely MEDIUM RISK
📅 Filed on BSE: 03 Nov 2026, 06:00 PM IST  ·  BSE ID: c1e886c0-e98d-41cb-8194-78cd148a1b8a
View Original BSE Filing (PDF)
💡
In Simple Terms
The company announced its Q2 FY27 financial results, showing a slight profit increase and revenue growth compared to last year.
🤖 AI Summary
  • Jenburkt Pharmaceuticals reported Standalone Net Profit After Tax of Rs. 1020.94 Lacs for Q2 FY27.
  • Revenue from Operations for the quarter ended 30 September 2026 was Rs. 4831.82 Lacs.
  • Total Comprehensive Income for the period stood at Rs. 964.08 Lacs.
  • The Board of Directors approved the unaudited financial statements for the quarter and half year ended 30 September 2026.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Revenue from Operations (Q2 FY27)
4831.82 Lacs
6.06%
Profit After Tax (Q2 FY27)
1020.94 Lacs
0.45%
Total Expenses (Q2 FY27)
3623.13 Lacs
8.79%
Earnings Per Share (Q2 FY27)
23.13 Rs.
0.43%
Profit After Tax (Half Year FY27)
1609.50 Lacs
-10.36%
🏢 How This Affects the Company
📈
Business Impact
The 6.06% year-over-year growth in Revenue from Operations to Rs. 4831.82 Lacs indicates an expansion in the company's core pharmaceutical business during Q2 FY27.
💰
Financial Impact
Net Profit After Tax saw a marginal 0.45% year-over-year increase to Rs. 1020.94 Lacs, while Total Expenses grew by 8.79% to Rs. 3623.13 Lacs, outpacing profit growth.
👥 What This Means For Shareholders
✅
Action Required
No action required from shareholders based on this financial results filing.
👤
Who Is Affected
Shareholders are affected by the company's financial performance, with Net Profit After Tax for Q2 FY27 at Rs. 1020.94 Lacs and Earnings Per Share of Rs. 23.13.
🔍
Management Signal
The Board's approval of the unaudited results indicates management's adherence to regulatory disclosure requirements and routine financial reporting.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 financial results — check for sustained revenue growth and expense management.
Board meeting outcomes — monitor for dividend declarations or other capital allocation decisions.
Updates on regulatory environment — observe any impact on pharmaceutical sector operations.
MEDIUM RISK Marginal profit growth in Q2 FY27 and a decline in half-year profit could indicate pressure on margins.
💡 Investor Takeaway
Jenburkt Pharmaceuticals reported Q2 FY27 Revenue from Operations at Rs. 4831.82 Lacs, a 6.06% YoY increase. Net Profit After Tax for the quarter was Rs. 1020.94 Lacs, up 0.45% YoY. Half-year Net Profit After Tax declined by 10.36% YoY to Rs. 1609.50 Lacs.
⚖️ Strengths & Concerns

✅ Positives

  • Revenue from Operations for Q2 FY27 increased to Rs. 4831.82 Lacs, showing a 6.06% growth compared to Rs. 4555.76 Lacs in Q2 FY26.
  • Net Profit After Tax marginally increased by 0.45% to Rs. 1020.94 Lacs in Q2 FY27 from Rs. 1016.34 Lacs in Q2 FY26.

⚠️ Concerns

  • Total Expenses rose by 8.79% to Rs. 3623.13 Lacs in Q2 FY27 compared to Rs. 3330.46 Lacs in Q2 FY26, outpacing revenue growth.
  • Employee benefit expenses increased by 6.76% to Rs. 1487.44 Lacs in Q2 FY27 from Rs. 1393.25 Lacs in Q2 FY26.
📅 Company Track Record
Jenburkt Pharmaceuticals reported Q1 FY27 Net Profit declined 24.47% YoY to Rs. 588.56 Lacs. This Q2 FY27 result shows a modest recovery in quarterly profit growth compared to the previous quarter's decline, though half-year profit remains lower year-on-year.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What is Jenburkt Pharmaceuticals' Net Profit After Tax for Q2 FY27?
Jenburkt Pharmaceuticals reported a Standalone Net Profit After Tax of Rs. 1020.94 Lacs for the quarter ended 30 September 2026 (Q2 FY27).
What was Jenburkt Pharmaceuticals' Revenue from Operations in Q2 FY27?
The Revenue from Operations for Jenburkt Pharmaceuticals in Q2 FY27 was Rs. 4831.82 Lacs, compared to Rs. 4555.76 Lacs in Q2 FY26.
How did Jenburkt Pharmaceuticals' half-year Net Profit After Tax perform in FY27?
For the half-year ended 30 September 2026 (FY27), Jenburkt Pharmaceuticals' Net Profit After Tax was Rs. 1609.50 Lacs, a decrease from Rs. 1795.52 Lacs in the corresponding half-year of FY26.
What were the Earnings Per Share (EPS) for Jenburkt Pharmaceuticals in Q2 FY27?
The Basic and Diluted Earnings Per Share (EPS) for Jenburkt Pharmaceuticals in Q2 FY27 stood at Rs. 23.13.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.